Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic
  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Aytu BioScience's (AYTU - NASDAQ: AYTU), MiOXSYS® Male Infertility Test, To Present Potential Best-In-Class Data

By: Issuewire

Aytu BioScience shares trade higher by 5% on MiOXSYS update

Miami Beach, Jun 19, 2019 (Issuewire.com) - Aytu BioScience, Inc. (NASDAQ: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products addressing significant medical needs, announced on Tuesday that multiple presentations highlighting the company's MiOXSYS® male infertility diagnostic system will be presented at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE). The ESHRE conference will be held in Vienna, Austria from June 23-26, 2019, and members of the Aytu BioScience management team, as well as leading researchers and clinicians, will be in attendance to provide the presentations. Shares closed the day on Tuesday higher by 5% to $1.90, its highest closing price for the month of June.

According to the release, 11 abstracts featuring MiOXSYS®, and the system's diagnostic output oxidation-reduction potential (ORP), have been accepted for presentation at ESHRE and will be presented by leading researchers in andrology, urology, and reproductive medicine from around the world. The news is the third important update for MiOXSYS® in as many months and is sending shares of AYTU higher as the company looks to add its fourth pipeline asset into its revenue stream. Notably, the presentations are expected to offer potential best-in-class data to target a multi-billion dollar infertility industry.

Moreover, the acceptance of 11 posters demonstrates the potential game-changing nature that MiOXSYS® can offer the infertility markets. Typically, one or two posters get accepted, and having 11 is drawing the attention of both investors and analysts who may need to revise their expectations higher for what MiOXSYS® may deliver to the AYTU business model

AYTU To Showcase MiOXSYS®

AYTU noted that two showcase presentations will be the first to report on new fertilization data that further expands the utility of the company's MiOXSYS® System as an advanced tool aiding in the diagnosis of male infertility. The presentations will take place on June 24, 2019, and are titled:

Title: "Prediction of successful ICSI cycles by oxidation-reduction potential (ORP) and sperm DNA fragmentation (SDF) analysis. A prospective study"
Presenter: Aqeel Morris, BSc, Department of Medical Biosciences
Institution: University of Western Cape, Bellville, South Africa
Presentation Time: 10:15 am CET


Title: "Relationship between oxidative stress in semen and the fertilizing capacity of the sperm - Evidence from the conventional IVF model in couples with unexplained infertility"
Speaker: Hassan Sallam MD, Ph.D., Professor in Obstetrics & Gynecology
Head of Alexandria Fertility & IVF Center
Institution: University of Alexandria, Alexandria, Egypt
Presentation Time: 5:00pm CET


About the data, Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, "With the recent publication of ESHRE's Recurrent Pregnancy Loss and Multiple Miscarriage guidelines, there is broadening awareness of the importance of accurately identifying the cause of male infertility, in part, through the assessment of DNA damage and direct measurement of seminal oxidative stress. MiOXSYS®, a CE marked diagnostic tool specifically measuring oxidative stress in semen, provides clinicians with a simple in-office test to quickly and accurately oxidative stress and help develop strategies to improve semen quality and male fertility."

Mr Disbrow continued, "Prior to the introduction of the MiOXSYS® System, there were limited, standardized and accurate options available to assess seminal oxidative stress and none that could be practically used in an office-based clinical setting. We are, therefore, pleased to continue to advance the body of clinical and scientific evidence to support the expanding use of the MiOXSYS® platform in office-based settings to enable broader clinical use around the world."

More MiOXSYS® Data Presented In The Global Markets

AYTU also provided news that additional presentations featuring MiOXSYS® are being made by leading andrologists, urologists, and reproductive medicine experts from a broad base of research institutions and infertility clinics around the world. Additional presentations will also be given at the Cleveland Clinic, the University of Antwerp, Belgium, the Medical University of Lublin, Lublin, Poland, and at the University of Osaka, Osaka, Japan. Further presentment of new data will also take place at the Centre Fertillia, Tunis, Tunisia, and at the Hamad Medical Corporation, Doha, Qatar.

Currently, the MiOXSYS® System is in use in over thirty countries around the world and is CE Marked and cleared by Health Canada, the Australian Therapeutic Goods Administration (TGA), and Mexico's COFEPRAS.

The MiOXSYS® device has been making headlines in recent months that are highlighting the system's advantages in both are speed and accuracy. Beyond that, however, the device also offers a practical solution compared to the expensive and sometimes bulky set-ups that have historically produced unreliable oxidative stress results.

Compared to the current standard of care, MiOXSYS® is aiming to replace common issues related to the antiquated systems currently in use that often provide misdiagnosis due to lack of maintenance and inaccurate calibration. In contrast, the MiOXSYS® System, unlike other tests that lack the ability to measure infertility related to oxidative stress, is used in real time in conjunction with standard semen analysis parameters (ejaculate volume, total sperm count, sperm concentration, total motility, progressive motility, and morphology) as an aid to assessing semen quality. The system is targeting adult males between 21-45 years of age.

The news on Tuesday adds to the momentum taking place with MiOXSYS® placements and comes on the heels of AYTU announcing that the device is expanding its presence into the United Kingdom, Australian, and Chinese markets through licensing deals and AYTU led strategic initiatives. The poster presentations, next week, may provide valuable insight into why the shares ran higher on Tuesday.

https://www.youtube.com/watch?v=SUQ1zh781p0&t=100s

Media Contact

Perceptive Advisors


editorial@soulstringreport.com

Miami Beach- via email

http://www.soulstringreport.com

Source :Perceptive Advisors

PDF Version : issuewire.com/pdf/2019/06/aytu-biosciences-aytu-nasdaq-aytu-mioxsys-male-infertility-test-to-present-potential-best-in-class-data-IssueWire.pdf

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.